4.5 Article

Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface

期刊

ACS MEDICINAL CHEMISTRY LETTERS
卷 11, 期 6, 页码 1269-1273

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.0c00111

关键词

BCL6; Protein-protein interactions; Covalent inhibitor; Sulfonyl fluoride

资金

  1. NIH [R01CA233800]

向作者/读者索取更多资源

B-cell lymphoma 6 (BCL6) is a transcriptional repressor frequently deregulated in lymphoid malignancies. BCL6 engages with number of corepressors, and these protein-protein interactions are being explored as a strategy for drug development. Here, we report the development of an irreversible BCL6 inhibitor TMX-2164 that uses a sulfonyl fluoride to covalently react with the hydroxyl group of Tyrosine 58 located in the lateral groove. TMX-2164 exhibits significantly improved inhibitory activity compared to that of its reversible parental compound and displays sustained target engagement and antiproliferative activity in cells. TMX-2164 therefore represents an example of a tyrosine-directed covalent inhibitor of BCL6 which demonstrates advantages relative to reversible targeting.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Medicinal

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug

Mingxing Teng, Marlise R. Luskin, Sandra W. Cowan-Jacob, Qiang Ding, Doriano Fabbro, Nathanael S. Gray

Summary: This review discusses the recent progress in the treatment of chronic myeloid leukemia (CML) and highlights the discovery and mechanism of action of allosteric inhibitors. The therapeutic potential of these inhibitors in delaying the development of acquired resistance is also explored. The article emphasizes the importance of understanding the fundamental regulatory mechanisms of kinases and presents key lessons learned from this program.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Multidisciplinary Sciences

Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections

Ram K. Modukuri, Zhifeng Yu, Zhi Tan, Hai Minh Ta, Melek Nihan Ucisik, Zhuang Jin, Justin L. Anglin, Kiran L. Sharma, Pranavanand Nyshadham, Feng Li, Kevin Riehle, John C. Faver, Kevin Duong, Sureshbabu Nagarajan, Nicholas Simmons, Stephen S. Palmer, Mingxing Teng, Damian W. Young, Joanna S. Yi, Choel Kim, Martin M. Matzuk

Summary: The study identified compounds with BET BD1 specificity, including CDD-787 and CDD-956, which exhibited high affinity and selectivity and demonstrated potent anti-leukemic activity in acute myeloid leukemia.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Andrology

Advancing ASMS with LC-MS/MS for the discovery of novel PDCL2 ligands from DNA-encoded chemical library selections

Qiuji Ye, Hassane Belabed, Yong Wang, Zhifeng Yu, Murugesan Palaniappan, Jian-Yuan Li, Stacey A. Kalovidouris, Kevin R. MacKenzie, Mingxing Teng, Damian W. Young, Yoshitaka Fujihara, Martin M. Matzuk

Summary: By developing a biophysical assay and using DNA-encoded chemical library (DECL) screening and off-DNA hit validation strategy, this study discovered a PDCL2 ligand for male contraception. The binding affinity between the PDCL2 ligand and PDCL2 was confirmed and determined by an affinity selection mass spectrometry assay combined with liquid chromatography tandem mass spectrometry (ASMS/LC-MS/MS).

ANDROLOGY (2023)

Article Chemistry, Medicinal

Development of potent and selective degraders of PI5P4Kγ

Wenzhi Ji, Eric S. Wang, Theresa D. Manz, Jie Jiang, Katherine A. Donovan, Xianmixinuer Abulaiti, Eric S. Fischer, Lewis C. Cantley, Tinghu Zhang, Nathanael S. Gray

Summary: Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks), consisting of three members (alpha, beta, and gamma) in mammals, have attracted attention as potential therapeutic targets due to their involvement in regulating various vital cellular signaling pathways. Among them, PI5P4K gamma shows distinct expression patterns and has been implicated in cancer and neurodegenerative diseases. A novel PI5P4K gamma degrader, JWZ-1-80, has been developed and characterized, exhibiting potent degradation activity and selective targeting towards PI5P4K gamma via the ubiquitin-proteasome system, which makes it a valuable tool compound for further investigations on the biological functions of PI5P4K gamma.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Multidisciplinary

E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance

Alexander Hanzl, Eleonora Barone, Sophie Bauer, Hong Yue, Radoslaw P. Nowak, Elisa Hahn, Eugenia V. Pankevich, Anna Koren, Stefan Kubicek, Eric S. Fischer, Georg E. Winter

Summary: Targeted protein degradation (TPD) is a new pharmacology approach that induces proximity between a protein of interest (POI) and an E3 ubiquitin ligase using small-molecule degraders. However, only a small percentage of E3s can be co-opted with degraders due to a lack of discovery approaches. This study focuses on NEDD8 conjugation and develops a scalable assay to identify compounds that alter the interactome of a specific E3 ligase.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2023)

Article Multidisciplinary Sciences

Structural basis of regulated m7G tRNA modification by METTL1-WDR4

Jiazhi Li, Longfei Wang, Quentin Hahn, Radoslaw P. Nowak, Thibault Viennet, Esteban A. Orellana, Shourya S. Roy Burman, Hong Yue, Moritz Hunkeler, Pietro Fontana, Hao Wu, Haribabu Arthanari, Eric S. Fischer, Richard I. Gregory

Summary: Chemical modifications of RNA play a crucial role in various biological processes. N-7-methylguanosine (m(7)G) is essential for the integrity and stability of a large group of tRNAs. The METTL1-WDR4 complex acts as a methyltransferase that modifies G46 in specific tRNAs, and its dysregulation is implicated in tumorigenesis. However, the mechanism of tRNA substrate recognition and regulation of METTL1-WDR4 remains unknown.

NATURE (2023)

Article Genetics & Heredity

Machine Learning Modeling of Protein-intrinsic Features Predicts Tractability of Targeted Protein Degradation

Wubing Zhang, Shourya S. Roy Burman, Jiaye Chen, Katherine A. Donovan, Yang Cao, Chelsea Shu, Boning Zhang, Zexian Zeng, Shengqing Gu, Yi Zhang, Dian Li, Eric S. Fischer, Collin Tokheim, X. Shirley Liu

Summary: Targeted protein degradation has become a promising therapeutic approach to eliminate previously undruggable proteins. This study developed a machine learning model, MAPD, to accurately predict the degradability of protein targets. The model showed potential for drug development targeting disease-causing proteins.

GENOMICS PROTEOMICS & BIOINFORMATICS (2022)

Article Chemistry, Multidisciplinary

Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader

Mingxing Teng, Jie Jiang, Eric S. Wang, Qixiang Geng, Sean T. Toenjes, Katherine A. Donovan, Nada Mageed, Hong Yue, Radoslaw P. Nowak, Jinhua Wang, Eric D. Fischer, Theresa S. Manz, Lewis C. Cantley, Nathanael S. Gray

Summary: This study identifies a highly potent PIP4K2C binder TMX-4102 and develops a bivalent degrader TMX-4153 that selectively degrades endogenous PIP4K2C. These findings provide important insights into the biological roles and therapeutic potential of PIP4K2C.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2023)

Article Multidisciplinary Sciences

Structures of BIRC6-client complexes provide a mechanism of SMAC-mediated release of caspases

Moritz Hunkeler, Cyrus Y. Jin, Eric S. Fischer

Summary: Tightly regulating apoptosis is crucial for the development of multicellular organisms and preventing diseases like cancer and neurodegeneration. Caspase activation is key to apoptosis, and inhibitor of apoptosis proteins (IAPs) are important for restraining caspase activity and can be targeted therapeutically. IAPs, in turn, are regulated by proapoptotic factors derived from mitochondria like SMAC and HTRA2. By studying the structures of human baculoviral IAP repeat-containing protein 6 (BIRC6) bound to SMAC, caspases, and HTRA2 through cryo-electron microscopy, we gain a molecular understanding of how BIRC6 inhibits caspase activity and how it is released by SMAC.

SCIENCE (2023)

Review Chemistry, Medicinal

Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches

Qi Miao, Vilas D. Kadam, Ayan Mukherjee, Zhi Tan, Mingxing Teng

Summary: Chemically induced proximity-based targeted protein degradation has become a prominent paradigm in drug discovery, and additional E3 ubiquitin ligases are being harnessed to enrich the arsenal of this therapeutic approach to tackle drug resistance.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Biochemical Research Methods

Diagnostic TR-FRET assays for detection of antibodies in patient samples

Hong Yue, Radoslaw P. Nowak, Daan Overwijn, N. Connor Payne, Stephanie Fischinger, Caroline Atyeo, Evan C. Lam, Kerri St. Denis, Lauren K. Brais, Yoshinobu Konishi, Romanos Sklavenitis-Pistofidis, Lindsey R. Baden, Eric J. Nilles, Elizabeth W. Karlson, Xu G. Yu, Jonathan Z. Li, Ann E. Woolley, Irene M. Ghobrial, Jeffrey A. Meyerhardt, Alejandro B. Balazs, Gali Alter, Ralph Mazitschek, Eric S. Fischer

Summary: Serological assays play an important role in diagnosing and monitoring infectious diseases. However, current methods have limitations in terms of technology and sample types. In this study, we developed a new serological assay based on TR-FRET technology, which showed exceptional versatility, scalability, and sensitivity. It outperformed or matched existing strategies in terms of sensitivity, specificity, and precision. This assay was successfully applied to measure antibody levels against different viruses and can be extended to other antigens.

CELL REPORTS METHODS (2023)

Article Biochemistry & Molecular Biology

Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead

Radoslaw P. Nowak, Leah Ragosta, Fidel Huerta, Hu Liu, Scott B. Ficarro, Justin T. Cruite, Rebecca J. Metivier, Katherine A. Donovan, Jarrod A. Marto, Eric S. Fischer, Breanna L. Zerfas, Lyn H. Jones

Summary: This study developed efficient PROTAC degraders using covalent CRBN ligands, which showed enhanced pharmacodynamics and expanded the scope of targets for heterobifunctional degraders.

RSC CHEMICAL BIOLOGY (2023)

Article Medicine, Research & Experimental

Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells

Rob S. Sellar, Adam S. Sperling, Mikolaj Slabicki, Jessica A. Gasser, Marie E. McConkey, Katherine A. Donovan, Nada Mageed, Dylan N. Adams, Charles Zou, Peter G. Miller, Ravi K. Dutta, Steffen Boettcher, Amy E. Lin, Brittany Sandoval, Vanessa A. Quevedo Barrios, Veronica Kovalcik, Jonas Koeppel, Elizabeth K. Henderson, Emma C. Fink, Lu Yang, Anthony Chan, Sheela Pangeni Pokharel, Erik J. Bergstrom, Rajan Burt, Namrata D. Udeshi, Steven A. Carr, Eric S. Fischer, Chun-Wei Chen, Benjamin L. Ebert

Summary: Targeted protein degradation, specifically degrading GSPT1, shows promise in cancer treatment, particularly acute myeloid leukemia. The study reveals the mechanism of GSPT1 degradation leading to impaired translation termination, activation of the integrated stress response, and cell death. The identification of key amino acids preventing GSPT1 degradation in mice and the efficacy of GSPT1-degrading drugs in vivo highlight the potential for cancer therapy.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Biochemistry & Molecular Biology

Cereblon covalent modulation through structure-based design of histidine targeting chemical probes

Justin T. Cruite, Geoffrey P. Dann, Jianwei Che, Katherine A. Donovan, Silas Ferrao, Scott B. Ficarro, Eric S. Fischer, Nathanael S. Gray, Fidel Huerta, Nikki R. Kong, Hu Liu, Jarrod A. Marto, Rebecca J. Metivier, Breanna L. Zerfas, Lyn H. Jones

Summary: This study demonstrates the rational targeting of a specific histidine residue in a protein binding site using sulfonyl exchange chemistry. Through structure-based drug design, potent covalent inhibitors and a labeling strategy were developed for the cereblon E3 ubiquitin ligase complex. This research expands the synthetic biology toolkit for site-selective protein modifications and contributes to the field of targeted protein degradation.

RSC CHEMICAL BIOLOGY (2022)

Article Oncology

IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia

Brandon J. Aubrey, Jevon A. Cutler, Wallace Bourgeois, Katherine A. Donovan, Shengqing Gu, Charlie Hatton, Sarah Perlee, Florian Perner, Homa Rahnamoun, Alexandra C. P. Theall, Jill A. Henrich, Qian Zhu, Radostaw P. Nowak, Young Joon Kim, Salma Parvin, Anjali Cremer, Sarah Naomi Olsen, Nicholas A. Eleuteri, Yana Pikman, Gerard M. McGeehan, Kimberly Stegmaier, Anthony Letai, Eric S. Fischer, X. Shirley Liu, Scott A. Armstrong

Summary: The combination targeting of IKAROS and MENIN is an effective therapeutic strategy for AML, disrupting leukemogenic transcriptional networks and resulting in synergistic killing of leukemia cells.

NATURE CANCER (2022)

暂无数据